Which drugs losing patents

Manufactured in the U. Several of its patents expire in October , potentially opening doors for generic versions. In the same month, Teva Pharmaceuticals Industries launched the first generic version of the drug, targeting patients with chronic obstructive pulmonary disease COPD.

According to Teva, Perforomist reaches annual sales in the U. So far, its generic version is the only one to hit the scene. When Denmark-based Lundbeck, loses patent exclusivity for one of its top-sellers — Northera — this year, the impact for the company will be huge.

According to Reuters , the company has forecasted that sales for Northera, which is used to treat symptoms related to neurogenic orthostatic hypotension, will plummet by half this year as the drug comes off patent.

Overall, the drop in Northera sales will contribute to the company seeing its revenue fall from On top of that, the company is gearing up to lose exclusivity of one of its key products — the opioid overdose drug, Narcan. The company is currently locked in a patent dispute with Teva Pharmaceutical Industries related to a generic version of the nasal spray.

As of June, judges ruled in favor of Teva, but Emergent will appeal. In , U. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws. For help please see our FAQs. This content is from: European Union. May 31 This content is from:. August 31 This content is from: Local Insights. April 14 This content is from: Features. June 02 This drug has forty-four patent family members in twenty-three countries. There are two drug master file entries for this API.

Additional details are available on the pralatrexate profile page. This drug has two hundred and thirteen patent family members in forty-five countries. Additional details are available on the ixabepilone profile page.

This drug has eighty-two patent family members in thirty-one countries. Additional details are available on the flibanserin profile page. There are three drug master file entries for this API. Additional details are available on the dichlorphenamide profile page. There are nineteen drug master file entries for this API. Additional details are available on the formoterol fumarate; mometasone furoate profile page.

This drug has ten patent family members in eight countries. Additional details are available on the sincalide profile page. This drug has twenty-four patent family members in fourteen countries. There are twenty-eight drug master file entries for this API. Additional details are available on the miconazole profile page. This drug has forty-four patent family members in thirty-six countries.

Additional details are available on the trabectedin profile page. This drug has twenty-nine patent family members in eighteen countries. Additional details are available on the fluocinolone acetonide; hydroquinone; tretinoin profile page. This drug has eight patent family members in eight countries.

Additional details are available on the sulfur hexafluoride lipid-type a microspheres profile page. This drug has twenty-five patent family members in twenty-one countries.

There are fifty-six drug master file entries for this API. Additional details are available on the acyclovir; hydrocortisone profile page. This drug has thirty-four patent family members in twenty-one countries. Additional details are available on the radium ra dichloride profile page. There are eleven patents protecting this drug.

Additional details are available on the cocaine hydrochloride profile page. This drug has twenty-seven patent family members in twenty countries. Additional details are available on the angiotensin ii acetate profile page. Serving leading biopharmaceutical companies globally:. Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.

The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information.

Visit the Subscription Options page for details on plans and pricing. Friedman, Yali. Alerts are available for users with active subscriptions. Preferred Citation: Friedman, Yali.